



Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

Card Guard Scientific Survival Ltd  
c/o Alex Gonorovsky  
2 Pekeris St  
Rehovot 76100  
Israel

JAN 16 2009

Re k082521  
Trade Name PMP<sup>4</sup> Easy2Check Personal Wireless Blood Pressure and Blood Glucose Monitor  
Regulation Number 21 CFR 862 1345  
Regulation Name Glucose Test System  
Regulatory Class Class II  
Product Codes NBW, CGA, DXN  
Dated December 2, 2008  
Received December 2, 2008

Dear Mr Gonorovsky

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to, registration and listing (21 CFR Part 807), labeling (21 CFR Parts 801 and 809), and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read 'C. Harper', with a long horizontal flourish extending to the right.

Courtney C. Harper, Ph.D.  
Acting Director  
Division of Chemistry and Toxicology  
Office of In Vitro Diagnostics Device  
Evaluation and Safety  
Center for Devices and Radiological Health

## Indication for Use

510(k) Number (if known): k082521

Device Name: PMP<sup>4</sup> Easy2Check Personal Wireless Blood Pressure and Blood Glucose Monitor

### Indication For Use:

The Easy2Check blood glucose and blood pressure monitoring system is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger and from the following alternative sites: the palm, the forearm, the upper-arm, the calf and the thigh. It is intended for use by healthcare professionals and people with diabetes mellitus at home as an aid in monitoring the effectiveness of diabetes control program. It is not intended for the diagnosis of or screening for diabetes mellitus. The alternative site testing in the systems can be used only during steady-state blood glucose conditions.

The system is also intended to be used to measure non-invasively the systolic and diastolic blood pressure and pulse rate of an adult individual, over age 16, at home. The blood pressure is measured by using a technique in which an inflatable cuff is wrapped around the arm. The cuff circumference is limited to 9.4"~13.8".

This system offers wireless communication function which is able to transmit the test result to other devices, such as PC.


Prescription Use   X    
(21 CFR Part 801 Subpart D)

And/Or

Over the Counter Use   X    
(21 CFR Part 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

  
\_\_\_\_\_  
Division Sign-Off  
Office of In Vitro Diagnostic Device  
Evaluation and Safety

510(k)   K082521